Format

Send to

Choose Destination
Ann Surg Oncol. 2017 Aug;24(8):2224-2232. doi: 10.1245/s10434-017-5821-7. Epub 2017 Mar 6.

Major Postoperative Complications Are a Risk Factor for Impaired Survival after CRS/HIPEC.

Author information

1
Department of Visceral and Transplantation Surgery, University Hospital of Zurich, Zurich, Switzerland.
2
Department of Visceral and Transplantation Surgery, University Hospital of Zurich, Zurich, Switzerland. Kuno.Lehmann@usz.ch.

Abstract

BACKGROUND:

Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is a combined treatment option for well-selected patients with peritoneal carcinomatosis (PC). The study aimed to identify factors influencing cancer-specific survival (CSS) and disease-free survival (DFS).

METHODS:

Data of 113 patients with colorectal or appendicular carcinomatosis from a single center operated between 2009 and 2014 were retrospectively collected and analyzed. Patients with high-grade tumors received standard perioperative chemotherapy, and patients with low-grade appendix tumors were directly operated. HIPEC was performed after radical CRS.

RESULTS:

Patients had carcinomatosis from appendix neoplasms in 63% (71/113), including low-grade and high-grade tumors, and colorectal cancer in 37% (42/113). Complete cytoreduction and HIPEC were possible in 67% of patients. Major morbidity occurred in 10.6% of patients, and mean follow-up was 28 months. For colorectal PC, median CSS and DFS were 40 and 12 months, respectively. Median DFS was 19 months for high-grade appendix tumors, while median CSS has not been reached. All patients with diffuse peritoneal adenomucinosis were still alive at time of analysis; rate of DFS was 96% for these patients after 3 years. Major postoperative complications (Clavien-Dindo IIIB or higher) and positive nodal state were associated with impaired CSS and DFS, while a peritoneal cancer index score of >10 was independently associated with impaired CSS.

CONCLUSIONS:

CRS/HIPEC offers a survival benefit in well-selected patients with PC. Major postoperative complications affect long-term oncologic outcome of these patients.

PMID:
28265776
DOI:
10.1245/s10434-017-5821-7
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center